Mass General Brigham investing $400 million in cancer care
BOSTON, Mass. (SHNS)–A week after conducting a second round of layoffs, Mass General Brigham announced a four-year, $400 million investment Tuesday into MGB Cancer as the health care giant braces for its split from Dana-Farber Cancer Institute.
Dr. Anne Klibanski, the system's CEO, acknowledged the layoffs as she announced the new investment, which involves renovations at Brigham and Women's Hospital and Faulkner Hospital to create new outpatient spaces.
Medicaid cuts may affect millions of Massachusetts residents
'As we navigate a period of challenging but pivotal change, I appreciate your continued dedication to our patients and to each other,' Klibanski wrote to employees in a Tuesday message, which was shared with the News Service. 'Our reorganization and financial stewardship will strengthen our foundation and enable us to make strategic investment in our patients, our care teams and our mission – preparing us for the ongoing headwinds facing our industry.'
MGB did not specify how many total workers lost their jobs, though The Boston Globe pegged it at around 1,500 positions across the layoffs in March and February.
The system said the layoffs affected mostly management and administrative positions, as MGB contended with a $250 million budget gap over the next two years. MGB argued the layoffs were needed to follow through with planned investments, including for workforce support, new clinical spaces and modernizing facilities.
Klibanski said the $400 million commitment will 'advance medical oncology, radiation oncology, cancer surgery, digital pathology, technology upgrades, support staffing, and patient navigation across MGB.' It will also be used to 'recruit top oncologists, implement digital pathology and enhance clinical support staffing,' MGB said.
'We begin this work now with the goal of ensuring that MGB Cancer is fully operational using our own resources, ready to serve patients before the conclusion of our current agreement with Dana-Farber in Fall 2028,' Klibanski wrote.
The state Public Health Council on Thursday is slated to vote on a determination of need request from Dana-Farber, which is looking to build its own cancer hospital with Beth Israel Deaconess Medical Center.
MGB Cancer plans to 'extensively' renovate three floors at the Brigham's Hale Building for Transformative Medicine in the Longwood area to support outpatient clinical space, plus one floor at Faulkner Hospital in Jamaica Plain, Klibanski said. MGB is also looking to relocate clinical, office and research space in the Longwood area, which the system said is 'currently housed mainly at the Dana-Farber Cancer Institute.'
In other efforts to bulk up oncology services, work is underway at Massachusetts General Hospital, where a new tower is expected to provide 'large-scale new resources for MGB Cancer patients,' Klibanski said. The system is also working on a new exam room and infusion capacity at MGH-Waltham.
'Our goal is to immediately begin to execute on our cancer strategy and provide space for both our existing and new cancer teams to work, perform research and care for patients,' Kevin Giordano, MGB's senior vice president of operations, said in an internal article shared with the News Service.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On February 5, 2025, Grizzly Research published a report entitled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud.' Grizzly stated that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue.' On this news, On this news, GeneDx's stock fell $4.84 per share, or 6.7%, to close at $67.18 per share on February 5, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Wall Street Journal
6 hours ago
- Wall Street Journal
Trump's ‘Big, Beautiful' Bill Gets Slimmed Down in Senate
WASHINGTON—President Trump's 'big, beautiful' bill is getting smaller just as Republicans head into a crucial week, after the Senate's rules arbiter decided several controversial provisions don't qualify for the special procedure the GOP is using to bypass Democratic opposition. The tax-and-spending megabill centers on extending Trump's 2017 tax cuts, delivering on the spirit of his campaign promises to eliminate taxes on tips and overtime, and providing big lump sums of money for border security and defense. Those new costs are partially offset by spending cuts, in particular to Medicaid.
Business Upturn
10 hours ago
- Business Upturn
ELV FRAUD ALERT: Elevance Health, Inc. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 11 Legal Deadline (NYSE:ELV)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al. , No. 25-cv-0092. Why was Elevance Sued for Securities Fraud? Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility. During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid. As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance's Medicaid members. What's more, the shift occurred to a degree that was not reflected in Elevance's rate negotiations or in its financial guidance for 2024. The Stock Declines as the Truth is Revealed On July 17, 2024, Elevance stated that it was now 'expecting second-half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population.' On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024. Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share ('EPS') expectations by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024. Click here if you suffered losses: What Can You Do? If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
